ATXS · As filed with the SEC
Astria Therapeutics cash flow statement, by quarter
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows · USD
| USD | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net loss | — | — | (33,709,000) | — | — | — | (19,928,000) | — |
| Reconciliation of net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | — | — | 3,839,000 | — | — | — | 2,754,000 | — |
| Right-of-use asset - operating lease | — | — | 281,000 | — | — | — | 153,000 | — |
| Amortization (accretion) of premium (discount) on investment securities | — | — | (1,053,000) | — | — | — | — | — |
| Other non-cash items | — | — | 20,000 | — | — | — | (665,000) | — |
| Changes in assets and liabilities: | ||||||||
| Prepaid expenses and other assets | — | — | (1,393,000) | — | — | — | (930,000) | — |
| Accounts payable | — | — | (625,000) | — | — | — | (651,000) | — |
| Accrued expenses | — | — | (1,088,000) | — | — | — | 334,000 | — |
| Operating lease liabilities | — | — | (290,000) | — | — | — | (161,000) | — |
| Net cash used in operating activities | — | — | (34,018,000) | — | — | — | (19,094,000) | — |
| Investing activities | ||||||||
| Purchases of short-term investments | — | — | (751,417,000) | — | — | — | (1,049,231,000) | — |
| Sales and maturities of short-term investments | — | — | 780,000,000 | — | — | — | 923,000,000 | — |
| Net cash provided by (used in) investing activities | — | — | 28,583,000 | — | — | — | (126,231,000) | — |
| Financing activities | ||||||||
| Proceeds from exercise of stock options and warrants | — | — | — | — | — | — | 4,633,000 | — |
| Proceeds from public offering, net of underwriting discounts and issuance costs | — | — | — | — | — | — | 117,172,000 | — |
| Proceeds from at-the-market offering, net of issuance costs | — | — | — | — | — | — | 20,002,000 | — |
| Net cash provided by financing activities | — | — | — | — | — | — | 141,807,000 | — |
| Net increase (decrease) in cash, cash equivalents and restricted cash | — | — | (5,435,000) | — | — | — | (3,518,000) | — |
| Cash, cash equivalents and restricted cash, beginning of period | 76,319,000 | 54,385,000 | 59,820,000 | 80,899,000 | 87,375,000 | 172,175,000 | 175,693,000 | 119,969,000 |
| Cash, cash equivalents and restricted cash, end of period | 96,280,000 | 76,319,000 | 54,385,000 | 59,820,000 | 80,899,000 | 87,375,000 | 172,175,000 | 175,693,000 |
| Supplemental disclosure of non-cash transactions: | ||||||||
| Public offering issuance costs in accounts payable and accrued expenses | — | — | — | — | — | — | 280,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.